Loading…
111, Inc. is projected to rise to $4.52 by 2027, a +8% move from its current price of $4.20. YI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $4.01 | $4.20 | $4.40 | 0.00% |
| Jul 15 | $3.93 | $4.20 | $4.49 | 0.00% |
| Jul 16 | $3.87 | $4.20 | $4.56 | 0.00% |
| Jul 17 | $3.82 | $4.20 | $4.61 | -0.01% |
| Jul 18 | $3.78 | $4.20 | $4.67 | -0.01% |
| Jul 19 | $3.74 | $4.20 | $4.71 | -0.01% |
| Jul 20 | $3.71 | $4.20 | $4.76 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.71 | $4.20 | $4.76 | -0.01% |
| Week 2 | $3.52 | $4.20 | $5.01 | -0.02% |
| Week 3 | $3.38 | $4.20 | $5.21 | -0.03% |
| Week 4 | $3.27 | $4.20 | $5.39 | -0.04% |
| Week 5 | $3.18 | $4.20 | $5.55 | -0.05% |
| Week 6 | $3.09 | $4.20 | $5.70 | -0.07% |
| Week 7 | $3.02 | $4.20 | $5.84 | -0.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People’s Republic of China. It operates through two segments, B2C and B2B, and offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides drugs, nutritional supplements and medical supplies and devices, personal care, and baby products.
In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool, as well as online consultation, e-prescription, and data services. Further, its pharmacies provide drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services.
It serves pharmacies, pharmaceutical companies, medical professionals, and marketplace sellers. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018.
111, Inc. was founded in 2010 and is headquartered in Shanghai, the People’s Republic of China.
111, Inc. (YI) is the asset operating in China’s healthcare market, with a diversified mix of online and offline services for pharmacies, pharmaceutical companies, and medical professionals. The current price is $4.20, and the company has a market cap of $36.95M, with a rank of 4661.
The near-term price picture shows a neutral posture as indicators navigate around key levels.
A major floor 36.0% below — a decisive break under it would weaken the trend.
The nearest floor, 11.9% below — buyers have tended to step in here.
The nearest ceiling, 30.2% above — a clean break opens room to run.
A major ceiling 82.9% above — clearing it would confirm fresh momentum.
Key YI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of YI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.08 | Buy | $4.12 | Buy |
| MA 10 | $4.12 | Buy | $4.14 | Buy |
| MA 20 | $4.21 | Sell | $4.30 | Sell |
| MA 50 | $5.02 | Sell | $4.89 | Sell |
| MA 100 | $6.00 | Sell | $5.33 | Sell |
| MA 200 | $5.25 | Sell | $5.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.74 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -3.94 | Neutral |
| Williams %R (14) | -21.88 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -2.10 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 78.12 | Neutral |
| TRIX (15) | -1.01 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 43.65 | Neutral |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 4.10 | Buy |
| ADX (14) | 22.94 | Sell |
| ATR (14) | 0.18 | Info |
The 30-day technical picture sits in neutral territory with RSI14 at 40. Price momentum and trend follow near-term support and resistance levels. The stock trades around the SMA50 of $5.02 and the SMA200 of $5.25, suggesting mild softness versus longer-term averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.76 | $4.20 | $5.52 | 0% | Neutral | |
| $3.35 | $4.52 | $6.55 | +8% | Neutral | |
| $3.07 | $4.36 | $6.70 | +4% | Neutral | |
| $2.68 | $3.98 | $6.40 | -5% | Neutral | |
| $2.45 | $3.78 | $6.31 | -10% | Neutral | |
| $2.76 | $4.43 | $7.62 | +5% | Neutral | |
| $3.60 | $5.98 | $10.59 | +42% | Bullish | |
| $3.39 | $5.82 | $10.57 | +39% | Bullish | |
| $3.10 | $5.49 | $10.20 | +31% | Bullish | |
| $3.17 | $5.80 | $11.03 | +38% | Bullish | |
| $4.03 | $8.58 | $17.80 | +104% | Bullish | |
| $5.95 | $13.23 | $30.43 | +215% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.76 | $4.20 | $5.28 | +0.00% |
| August 2026 | $3.68 | $4.43 | $5.54 | +5.47% |
| September 2026 | $3.44 | $4.19 | $5.34 | -5.32% |
| October 2026 | $3.31 | $4.08 | $5.28 | -2.65% |
| November 2026 | $3.39 | $4.21 | $5.52 | +3.22% |
| December 2026 | $3.32 | $4.17 | $5.52 | -1.16% |
Click any year to see its month-by-month YI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, YI could reach as high as $5.52, with a base case around $4.20 and support toward $2.76 — roughly 0% from $4.20. A consolidation phase looks the most probable path here.
Expect YI to range from $3.35 to $6.55 through 2027. The $4.52 average target implies a +8% move from current prices. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
The YI price prediction for 2028 points to an average of $4.36 (low $3.07, high $6.70) — a potential gain of +4% on today's $4.20. A consolidation phase looks the most probable path here.
In 2029, YI is projected to trade between $2.68 and $6.40, averaging $3.98 — a potential decline of -5% from today's $4.20. That is -9% versus the projected 2028 average. Price action looks broadly range-bound.
111, Inc.'s 2030 outlook centres on $3.78, within a $2.45 to $6.31 range. That is -5% versus the projected 2029 average. That marks a -10% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, YI could reach as high as $7.62, with a base case around $4.43 and support toward $2.76 — roughly +5% from $4.20. Price action looks broadly range-bound.
Expect YI to range from $3.60 to $10.59 through 2032. The $5.98 average target implies a +42% move from current prices. That is up +35% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The YI price prediction for 2033 points to an average of $5.82 (low $3.39, high $10.57) — a potential gain of +39% on today's $4.20. Momentum favours further upside here.
In 2034, YI is projected to trade between $3.10 and $10.20, averaging $5.49 — a potential gain of +31% from today's $4.20. That is -6% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
111, Inc.'s 2035 outlook centres on $5.80, within a $3.17 to $11.03 range. That is up +6% on the projected 2034 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2040, YI could reach as high as $17.80, with a base case around $8.58 and support toward $4.03 — roughly +104% from $4.20. Buyers look set to stay in control over this stretch.
Expect YI to range from $5.95 to $30.43 through 2050. The $13.23 average target implies a +215% move from current prices. That is up +54% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in YI today (≈ 238.095238 YI) could be worth
$3,150.05
+$2,150.05 (+215%) by 2050 · US Dollar
Based on the average projected YI price of $13.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in YIwould be worth at today's price.
$1,000 invested in YI on Jul 10, 2025 (≈ 132.978724 YI) would be worth
$558.51
-$441.49 (-44.1%) today · 0.56× · US Dollar
Based on a YI entry price of $7.52 vs. today's $4.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.13 | $1,016.95 | +1.7% |
| 1 month ago | $4.36 | $963.3 | -3.7% |
| 3 months ago | $6.58 | $638.3 | -36.2% |
| 6 months ago | $3.65 | $1,150.68 | +15.1% |
| 1 year ago | $7.52 | $558.51 | -44.1% |
| All time (5.0y) ago | $7.39 | $568.34 | -43.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our YI forecast.
Our base-case forecast reaches $8.40 around 2040.
Implied market cap at $8.40: $43.65M
Forecasts show a mixed near term, with 2026 average near $4.20 and a gradual move through 2029, including a dip to an average of $3.97 and a negative ROI of -5.5 in 2029 and -9.8 in 2030. Starting in 2032, the outlook turns more favorable, with 2032 average $5.97 and ROI 42.2, followed by 2033 average $5.82 and ROI 38.5, 2034 average $5.49 and ROI 30.8, and 2035 average $5.80 and ROI 38. From 2040 onward, the forecast shows stronger upside: 2040 average $8.59 and ROI 104.4, and 2050 average $13.21 and ROI 214.6, with bullish sentiment noted for 2032 and beyond.
These figures are estimates and not guarantees, and they carry inherent uncertainty and risk.
Tap a question to reveal the answer.
Avg $3.79, min $2.45, max $6.32, ROI -9.8, sentiment NEUTRAL.
Near-term forecasts show mixed results with 2026‑2029 averages around the low to mid $4s and ROI values ranging from 0 to -5.5 in 2029. Longer-term outlook turns bullish from 2032 onward, with 2032 average $5.97 and ROI 42.2, 2040 average $8.59 and ROI 104.4, and 2050 average $13.21 and ROI 214.6.
Yes, the forecast lists max values above $10 in several years: 2032 max $10.58, 2033 max $10.57, 2034 max $10.22, 2035 max $11.01, 2040 max $17.81, and 2050 max $30.39.
RSI14 is 40; SMA50 is $5.02; SMA200 is $5.25; 30-day range is $3.08 to $5.73; support is $3.70 and resistance is $5.47.
Current price is $4.20; market cap is $36.95M; rank is 4661.
111, Inc. Community Discussion
0Share your 111, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.